Terms: = Sarcomas AND CRTC1, Q6UUV9, 23373, ENSG00000105662, KIAA0616, TORC1, MECT1, WAMTP1, FLJ14027 AND Treatment
4 results:
1. Statistical analysis plan for the Dual mTorc Inhibition in advanCed/recurrent Epithelial ovarian, fallopian tube or primary peritoneal cancer (of clear cell, endometrioid and high-grade serous type, and carcinosarcoma) trial (DICE).
de la Rosa CN; Krell J; Day E; Clarke A; Reddi M; Webber L; Fiorentino F
Trials; 2022 Jan; 23(1):13. PubMed ID: 34986897
[TBL] [Abstract] [Full Text] [Related]
2. Synergistic activity of mtorc1/2 kinase and MEK inhibitors suppresses pediatric low-grade glioma tumorigenicity and vascularity.
Arnold A; Yuan M; Price A; Harris L; Eberhart CG; Raabe EH
Neuro Oncol; 2020 Apr; 22(4):563-574. PubMed ID: 31841591
[TBL] [Abstract] [Full Text] [Related]
3. KIT-Dependent and KIT-Independent Genomic Heterogeneity of Resistance in Gastrointestinal Stromal Tumors - torc1/2 Inhibition as Salvage Strategy.
Mühlenberg T; Ketzer J; Heinrich MC; Grunewald S; Marino-Enriquez A; Trautmann M; Hartmann W; Wardelmann E; Treckmann J; Worm K; Bertram S; Herold T; Schildhaus HU; Glimm H; Stenzinger A; Brors B; Horak P; Hohenberger P; Fröhling S; Fletcher JA; Bauer S
Mol Cancer Ther; 2019 Nov; 18(11):1985-1996. PubMed ID: 31308077
[TBL] [Abstract] [Full Text] [Related]
4. Dual blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) pathways synergistically inhibits rhabdomyosarcoma cell growth in vitro and in vivo.
Renshaw J; Taylor KR; Bishop R; Valenti M; De Haven Brandon A; Gowan S; Eccles SA; Ruddle RR; Johnson LD; Raynaud FI; Selfe JL; Thway K; Pietsch T; Pearson AD; Shipley J
Clin Cancer Res; 2013 Nov; 19(21):5940-51. PubMed ID: 23918606
[TBL] [Abstract] [Full Text] [Related]
